Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy

Phase 3

Completed

• Conditions: Gastric Cancer; Colon Nos Polypectomy Tubular Adenoma; Gastric Adenoma
• Interventions: Drug: Menthol

• Registration Number: NCT01411189
• Lead Sponsor: Nihon Pharmaceutical Co., Ltd

Brief Summary

Patients who require therapeutic upper gastrointestinal endoscopy, such as polypectomy, endoscopic hemostasis, percutaneous endoscopic gastrostomy (PEG), endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), will receive an intragastric spraying of NPO-11. The efficacy of NPO-11 as an anti-peristaltic agent for the endoscopic therapeutic procedures will be evaluated based on the proportion of patients with suppressed gastric peristalsis during the procedures. The degree of gastric peristalsis is assessed by an independent committee.

The safety of NPO-11 will be evaluated based on adverse events and adverse drug reactions (ADRs) observed between administration and seven days after administration.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-08-03
• Study First Submitted QC: 2011-08-05
• Study First Posted: 2011-08-08
• Study Start: 2011-09
• Primary Completion: 2012-05
• Status Verified: 2012-06
• Study Completion: 2012-06
• Last Update Submitted: 2012-06-27
• Last Update Posted: 2012-06-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

Inpatients or outpatients of either sex who require therapeutic upper gastrointestinal endoscopy and meet criteria (1), (4), (6) and one from (2), (3) or (5) in the study. Patients have to provide written informed consent for voluntary participation in the study. The criteria (2) to (4) will be confirmed by the endoscopic observation just before starting the intended treatment.

1. Patients who require therapeutic upper gastrointestinal endoscopy (polypectomy, endoscopic hemostasis, PEG, EMR and ESD)
2. Patients with a differentiated-type intramucosal gastric cancer located in the upper or middle third of the stomach (≤2 cm in size, no ulcer finding, EMR or ESD)
3. Patients with a gastric adenoma (≤2 cm in size, no ulcer finding, EMR or ESD)
4. Patients with an a single intended lesion for the treatment
5. Patients without experience of PEG tube placement in case of PEG tube placement
6. Patients who are older than 20 years at the time of consent

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from the study beforehand. The criteria (3) and (4) will be confirmed by the endoscopic observation just before starting the intended treatment.

1. Patients with a history of surgery to the upper gastrointestinal tract
2. Patients who require emergency endoscopy
3. Patients with severe gastric stenosis or deformation which makes observation of gastric peristalsis difficult
4. Patients who require emergency endoscopic treatment except for the intended lesion
5. Patients with an ongoing cancer treatment (chemotherapy or radiotherapy)
6. Patients with pacemaker
7. Patients with known bleeding tendency or Patients with difficulty of antithrombogenic agents withdrawal
8. Patients with a history of shock or hypersensitivity to l-menthol or peppermint oil
9. Pregnant or lactating women, women of childbearing potential, or women who plan to become pregnant during the study
10. Patients who have received other investigational drugs within four months before consent or who are participating in other clinical studies
11. Patients otherwise ineligible for participation in the study in the investigator's opinion

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Menthol	Menthol	20 mL NPO-11

Primary Outcome Measures

Name	Time	Method
The proportion of patients had no or mild peristalsis during the therapeutic procedures	60 minutes	No or mild gastric peristalsis is defined as when patients have no or suppressed gastric peristalsis during the therapeutic procedure (for 45 s). The degree of gastric peristalsis in the time periods is assessed by an independent committee.

Secondary Outcome Measures

Name	Time	Method
Duration of peristalsis-suppressing effect	60 minutes
Difficulty level of the therapeutic procedure	60 minutes
Adverse events and adverse drug reactions	7 days

Trial Locations

Locations (1)

Nihon Pharmaceutical Co., Ltd; 🇯🇵 Tokyo, Japan